#PRESS: Menopause doesn't have to mean less weight loss. New phase 3 trial data show an average weight loss of 25% across menopause stages, offering women new hope for meaningful weight loss and lasting health. Get all the details in our press release: novonordisk.com/content/nnco…

#PRESS: In an analysis of adults with obesity and excess liver fat, nearly 9 in 10 who received treatment reached normal liver fat levels after 72 weeks. Measured liver fat fell from 8.8% to 3.1% in the treatment group. Read more about the findings, presented at EASD 2026, in our press release: novonordisk.com/content/nnco…

#PRESS: For people living with obesity or type 2 diabetes, health is about more than a number on the scale. In one study, brain scans showed changes in responses to high-calorie foods. Separate research in adults with type 2 diabetes found less fat in the liver and pancreas, while early findings suggest bone health was maintained despite weight loss. Get the details from our new research, presented at EASD 2026, in our press release: novonordisk.com/content/nnco…

#PRESS: What happened when people switched from weight-loss injections to a pill? Learn more about the findings, presented at EASD 2026, in our press release: novonordisk.com/content/nnco…

#PRESS: For people living with type 2 diabetes, heart health is an important part of care. In a real-world study, those who switched to another medicine had a 6% higher relative risk of serious heart events than those who increased the dose of their existing medicine. Get all the details presented at EASD 2026 in our press release here: novonordisk.com/news-and-med…

We’ve entered an exclusive license agreement with Hengrui Pharma to develop a potential once-weekly pill for people living with obesity or type 2 diabetes. Learn more in our press release here: novonordisk.com/content/nnco…

Growing up healthy should be a given. That’s why we’re expanding our partnership with @UNICEF — with a shared ambition to reach more than 80 million children by 2030. Learn more in our press release here: novonordisk.com/content/nnco…

#PRESS: New results from phase 3 investigational next-generation diabetes and obesity medicine - taking our unique amylin innovation one step closer to people living with obesity and diabetes. Get all the details in our press release here: novonordisk.com/news-and-med…

We're hosting a Capital Markets Day (CMD) in London providing an update to our Corporate strategy and strategic ambitions for 2030. Learn more in our press release here: novonordisk.com/content/nnco…

#PRESS: A milestone over 20 years in the making: The EU gives its first positive opinion on a growth hormone treatment for unexplained short stature, bringing new support to affected children and families. Get all the details in our press release here: novonordisk.com/news-and-med…

#PRESS: Our first once-monthly treatment for haemophilia A is now one step closer to approval in EU, bringing more options for people living with haemophilia A.  Learn more in our company announcement here: novonordisk.com/content/nnco…

#PRESS: New data published in the Journal of Thrombosis and Haemostasis bring encouraging news for people living with haemophilia A. Get all the details in our press release here: novonordisk.com/news-and-med…

Behind every scientific breakthrough is a person waiting for it - a patient, a family, a caregiver hoping for better treatment options. We are therefore excited to announce a new partnership with @AnthropicAI, so our scientists, by the use of AI, can bring new medicines to the people who need them, faster. Learn more in the press release here: novonordisk.com/content/nnco…

#PRESS: At EASD 2026 in Milan, we'll share new data across obesity, type 2 diabetes, cardiovascular disease, and kidney and liver health. These conditions rarely show up alone. Understanding how they connect is how we can bring better health to many more people. Find all the details in the press release here: novonordisk.com/news-and-med…

Lasting Health Starts Now. Find out why in our press release here: novonordisk.com/news-and-med…

#PRESS For many children living with obesity - and their families - everyday life can be challenging. Results from a large late-stage clinical trial show that 40.4% of children moved from the obesity BMI category to the overweight or even healthy-weight category.    Learn more in the press release here: novonordisk.com

#PRESS Novo Nordisk wins Dutch court injunction protecting patients from unapproved, unlawful compounded semaglutide nasal spray. Read more in the press release here: novonordisk.com/content/nnco…